Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor
Authors:
- 1 November 2021
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 100 (5) , 491-501
Abstract
The neurotrophins are a family of growth factors that bind and activate two types of cell surface receptors: the Trk family, and p75. TrkA, TrkB or TrkC are bound preferentially by NGF, BDNF, or NT3 to activate neuroprotective signals. The p75 receptors are activated by all neurotrophins. Paradoxically, in neurodegenerative disease p75 is upregulated and mediates neurotoxic signals. Hence, the receptors can mediate opposite activities in a ligand-dependent manner. To test neuroprotection strategies, we engineered NT3 to broadly activate Trk receptors (mutant D), to reduce p75 binding (mutant RK), or combining these features in a molecule that activates TrkA, TrkB and TrkC with reduced p75 binding (mutant DRK). In mouse neurodegenerative disease models in vivo, the DRK protein protects a broader range of stressed neurons and is a superior therapeutic agent compared to D, to RK, or to wild-type neurotrophins. This work rationalizes neuroprotective therapeutic strategies based on the biology of each receptor subtype in disease states. Significance Statement Neurotrophins are growth factors NGF BDNF and NT3, each can activate a TrkA or TrkB or TrkC receptor respectively, and all can activate a p75 receptor. Trks and p75 mediate opposite signals. We report the engineering of a protein that activates all Trks, combined with low p75 binding, as an effective therapeutic agent in vivo.Keywords
This publication has 42 references indexed in Scilit:
- A multifunctional neurotrophin with reduced affinity to p75NTR enhances transplanted Schwann cell survival and axon growth after spinal cord injuryExperimental Neurology, 2013
- Chronic and Acute Models of Retinal Neurodegeneration TrkA Activity Are Neuroprotective whereas p75NTR Activity Is Neurotoxic through a Paracrine MechanismJournal of Biological Chemistry, 2010
- ProNGF induces TNFα-dependent death of retinal ganglion cells through a p75 NTR non-cell-autonomous signaling pathwayProceedings of the National Academy of Sciences, 2010
- An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptorsDevelopmental Neurobiology, 2009
- Identification of Critical Residues within the Conserved and Specificity Patches of Nerve Growth Factor Leading to Survival or DifferentiationJournal of Biological Chemistry, 2009
- Inhibition of p75NTR in glia potentiates TrkA-mediated survival of injured retinal ganglion cellsMolecular and Cellular Neuroscience, 2009
- TrkA Receptor “Hot Spots” for Binding of NT-3 as a Heterologous LigandJournal of Biological Chemistry, 2007
- Neurotrophic rationale in glaucoma: A TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cellsin vivoDevelopmental Neurobiology, 2007
- Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkAJournal of Neuroscience, 2004
- Mutational studies of conserved residues in the dimer interface of nerve growth factorProtein Science, 1996